Regulation 2

“allied health professional” has the meaning given by section 2 of the Allied Health Professions Act 2011;

“approved allied health professional” means any allied health professional who is approved by the Minister for Health for the purposes of this Part;

“approved cancer drug” means any active ingredient (or combination of active ingredients) in the dosage form and strength listed in the CDL and administered for the corresponding clinical indication listed in the CDL;

“approved centre” means any centre in a hospital or clinic approved by the Minister for Health for renal dialysis treatment;

“approved chronic illness treatment” means any medical treatment or psychiatric treatment in respect of any chronic illness which is approved by the Minister for Health for the purposes of this Part;

“approved CIT medical institution” means any centre, clinic, hospital or other premises which offers medical treatment or psychiatric treatment and which the Minister for Health has approved for the purposes of approved chronic illness treatments under this Part;

“approved clinic” means any medical clinic approved by the Minister for Health for the purposes of this Part;

“approved community hospital” means any premises which, in the opinion of the Minister for Health, provide an intermediate level of care for out‑patients and in‑patients who have simple ailments which do not require specialist medical and nursing care and are approved by that Minister for the purposes of this Part;

“approved convalescent hospital” means any premises which provide in‑patient medical care for the recovery or rehabilitation of patients and are approved by the Minister for Health for the purposes of this Part;

“approved day hospice” means any premises (other than a home) which are used for out‑patient medical treatment and care of terminally ill patients and are approved by the Minister for Health for the purposes of this Part;

“approved day hospital” means any premises which provide day rehabilitative assessment and treatment of patients and are approved by the Minister for Health for the purposes of this Part;

“approved day rehabilitation centre” means any centre operating at or within a location other than an approved hospital, which provides approved rehabilitation treatment and is approved by the Minister for Health for the purposes of this Part;

“approved day surgery centre” means any centre which provides day surgical treatment to a member or the member’s dependant and is approved by the Minister for Health for the purposes of this Part;

“approved high‑cost drug”, in relation to a clinical indication specified in the first column of the Eighth Schedule, means any active ingredient (or combination of active ingredients) specified in the HCDL and administered in the dosage form and strength specified in the HCDL for that clinical indication;

“approved home palliative care provider” means any person who provides home palliative care and is approved by the Minister for Health for the purposes of this Part;

“approved hospital” means any hospital approved by the Minister for Health for the purposes of this Part;

“approved in‑patient hospice” means any premises which are used for in‑patient medical treatment and care of terminally ill patients and are approved by the Minister for Health for the purposes of this Part;

“approved in‑patient palliative care service provider” or “approved IPC provider” means any premises that provide in‑patient palliative care and are approved by the Minister for Health for the purposes of this Part;

“Approved Indications for PBT” means Approved Indications for Use of Proton Beam Therapy in Treatment published on the website of the Ministry of Health at https://www.moh.gov.sg;

“approved medical institution” means any of the following:

“approved medical practitioner” means any medical practitioner who is approved by the Minister for Health or such other person as the Minister for Health may appoint for the purposes of this Part;

“approved MIC@Home treatment provider” means any approved hospital designated by the Minister for Health for the purposes of the MIC@Home programme;

“approved out‑patient parenteral nutrition” means any parenteral nutrition that is provided by an approved hospital to an out‑patient, and is approved by the Minister for Health for the purposes of this Part;

“approved rehabilitation treatment” means any of the following types of rehabilitation treatments provided by an approved day rehabilitation centre to an out‑patient:

“approved remote consultation”, in relation to any Sixth Schedule treatment, means the Sixth Schedule treatment, including any consultation for that Sixth Schedule treatment, received by remote provision approved under section 11B of the Healthcare Services Act 2020 as a service delivery mode for that Sixth Schedule treatment;

“approved renal dialysis premises” means any premises that the Minister for Health approves for the type of renal dialysis treatment received;

“approved screening” means any health screening which is approved by the Minister for Health for the purposes of this Part;

“approved screening centre” means any premises or conveyance specified in a licence granted or deemed to be granted under the Healthcare Services Act 2020 for the provision of any of the following licensable healthcare services, in respect of which there is a valid approval by the Minister for Health for the purposes of this Part, whether approved before, on or after 3 January 2022:

“approved Third Schedule treatment provider” means any hospital or medical clinic that provides any Third Schedule treatment and is approved by the Minister for Health for the purposes of this Part;

“approved treatment package” means a course of one or more of the following which lasts not more than one year, which is approved by the Minister for Health for the purposes of this Part, and which complies with such terms and conditions as the Minister for Health may impose:

“approved vaccination” means any vaccination (including any vaccination against Hepatitis B or pneumococcal disease) which is approved by the Minister for Health for the purposes of this Part;

“cancer drug” means any drug, including any approved cancer drug, used for the treatment of neoplasms;

“cancer drug treatment” means —

“cancer scan or diagnostic test” means any scan or diagnostic test (which may include magnetic resonance imaging (MRI), computerised tomography (CT) scans, positron emission tomography (PET) scans, ultrasound imaging, x‑rays, mammograms and blood tests) performed —

“CDL” means the Cancer Drug List published on the website of the Ministry of Health at https://www.moh.gov.sg;

“chemotherapy”, in relation to the treatment of neoplasms, means the administration of tested and approved chemotherapeutic agents by the usual and known routes;

“co‑payment amount”, in relation to a member or the member’s dependant, means the amount which the member or the member’s dependant (as the case may be) is responsible for paying in respect of any approved chronic illness treatment or approved treatment package, as specified in regulation 14(1)(a);

“co‑payment percentage”, in relation to a member or the member’s dependant, means the percentage of the charge for any approved chronic illness treatment or approved treatment package which the member or the member’s dependant (as the case may be) is responsible for paying, as specified in regulation 14(1)(a) and (b);

“CTGTP” means any health product (within the meaning of the Health Products Act 2007) categorised as a cell, tissue or gene therapy product in the First Schedule to the Health Products Act 2007;

“CTGTP treatment” means the administration of a CTGTP for a clinical indication, as specified in the Seventh Schedule;

“day surgical treatment” means any surgical treatment received by a person who is admitted and discharged on the same day;

“dependant”, in relation to a member, means any of the following:

“First Schedule treatment” means any medical treatment specified in the First Schedule;

“HCDL” means the High‑Cost Drug List published on the website of the Ministry of Health at https://www.moh.gov.sg;

“high‑cost drug treatment” means the administration of any approved high‑cost drug for a clinical indication as specified in the first column of the Eighth Schedule;

“home”, in relation to a person, means any premises (other than an approved medical institution) in which the person is residing;

“home palliative care” means any palliative care for a terminally ill patient provided at the home of the patient;

“home ventilation and respiratory support programme” means a programme administered by Tan Tock Seng Hospital Pte Ltd that provides ventilation or respiratory support equipment for use by a patient at the patient’s home, and any ancillary medical care or service relating to the use of the equipment;

“in‑patient” means a patient who —

“last medical bill”, in relation to a member who has died on or after 1 July 2006 in an approved medical institution before the member’s discharge from the approved medical institution, means the bill for charges incurred in respect of the medical or psychiatric treatments which the member received in the approved medical institution;

“life support home care” means the provision of —

“living donor organ transplant” has the meaning given by the Human Organ Transplant Act 1987;

“medical clinic” means any premises used by one or more approved medical practitioners for the diagnosis or treatment of persons but does not include any such premises which form part of the premises of an approved hospital;

“medical practitioner” means any medical practitioner registered under the Medical Registration Act 1997 or any dentist registered under the Dental Registration Act 1999;

“medical treatment” includes —

“medical treatment for conception” means —

“medical treatment for fertility preservation” means —

“Medisave healthcare provider” has the meaning given by section 67A of the Act;

“member” includes a member who is an undischarged bankrupt;

“MIC@Home programme” means a health programme approved by the Minister for Health, and known by that name or as the Mobile Inpatient Care@Home programme;

“MIC@Home treatment” means any of the following provided by an approved MIC@Home treatment provider to a patient under the MIC@Home programme:

“multiple neoplasms” means 2 or more neoplasms that —

“negative pressure wound therapy” means the use of vacuum dressing to promote wound healing;

“neoplasm” means an abnormal growth of a tissue in a part of the body, that can be benign or malignant;

“Ninth Schedule treatment” means any medical treatment specified in the Ninth Schedule;

“non‑qualifying medical treatment” means any medical treatment for which no withdrawal from a medisave account may be made under this Part;

“organ transplantation costs” means —

“out‑patient” means a patient other than an in‑patient or a patient receiving day surgical treatment;

“out‑patient scan” means any scan (including any magnetic resonance imaging (MRI), computerised tomography (CT) scans, positron emission tomography (PET) scans, ultrasound imaging and mammograms) instructed by an approved medical practitioner and performed on an out‑patient for the purpose of providing —

“paediatric patient”, in relation to life support home care, means —

“parenteral antibiotics therapy” means the administration of any subsidised antibiotic through injection or infusion;

“pasteurised donated human milk” means human breast milk that has been pasteurised and is provided by KK Women’s and Children’s Hospital Pte. Ltd. as part of any medical treatment for a child below one year of age;

“pre‑delivery medical treatment” means any medical treatment prescribed by a medical practitioner that is received by a pregnant woman in relation to her pregnancy before the delivery of a child or the termination of her pregnancy;

“prescribed person”, in relation to a member, means a person —

“psychiatric treatment” includes any therapeutic procedure given to control and relieve any psychiatric symptom or to prevent its recurrence, but does not include any treatment for any mental illness or personality disorder classified by the Minister for Health as a medical condition;

“qualifying combined treatment” means one or more of the following treatments provided (whether on a single day or over a period of days) to a patient consecutively and in any order:

“radiosurgery treatment” means the treatment of neurosurgical or neurological disorders using any of the following:

“radiotherapy treatment” means the treatment of any malignant disease or certain benign condition with ionising radiation delivered externally or internally by sealed or unsealed radionuclides and irradiating apparatus as specified in the First Schedule;

“remote provision” has the meaning given by the Healthcare Services Act 2020;

“renal dialysis treatment” means any of the following:

“repetitive transcranial magnetic stimulation” means a non‑invasive brain stimulation procedure using magnetic pulses delivered through an electromagnetic coil placed against a patient’s scalp and carried out over one or more treatment sessions;

“Singapore Gamma Knife Centre” means any premises which provide gamma knife treatment for the care of in‑patients and are approved by the Minister for Health for the purposes of this Part;

“Sixth Schedule treatment” means each type of treatment specified in the first column of the Sixth Schedule;

“specified emergency department” means any premises that provide emergency medicine services and are specified by the Minister for Health for the purposes of this Part;

“specified organ” has the meaning given by the Human Organ Transplant Act 1987;

“specified out‑patient treatment” means any out‑patient medical treatment or out‑patient psychiatric treatment, approved by the Minister for Health for the purposes of regulation 21B;

“subsidised antibiotic” means an antibiotic in the dosage form and strength listed on the List of Subsidised Drugs published on the website of the Ministry of Health at https://www.moh.gov.sg/managing-expenses/schemes-and-subsidies/list-of-subsidised-drugs;

“surgical treatment” means any surgical treatment approved by the Minister for Health for the purposes of this Part;

“Third Schedule treatment” means any medical treatment specified in the Third Schedule;

“treatment for sexual sterilisation” has the meaning given by the Voluntary Sterilisation Act 1974;

“treatment of neoplasms” means the treatment of malignant neoplasms, certain benign neoplasms and neoplasms of uncertain behaviour.